Head, Oncology Clinical Development - ADCs
Leads end-to-end clinical development of an antibody-drug conjugate (ADC) oncology asset across multiple tumor types, from first-in-human through registrational trials and launch. Responsible for shaping clinical strategy, overseeing global trials, engaging with regulatory authorities, and integrating translational research and innovative approaches like AI/ML and real-world evidence. Acts as senior clinical representative in governance forums and external scientific engagements.